Background: Electrophysiology study (EPS) is an important part of the diagnosis and
| INTRODUCTION
Electrophysiologic characteristics of the heart may change under various physiologic states. Sympathetic and parasympathetic influences alter the heart rate and blood pressure in response to exercise, for example. [1] [2] [3] [4] [5] [6] [7] [8] The basic electrophysiology study (EPS) includes careful measurement of both baseline conduction intervals as well as intervals under stressful conditions. Because of its nearly pure beta-adrenergic stimulation, isoproterenol is the sympathomimetic drug of choice for infusion during EPS. To date, the largest series of cases involving tilt table testing, EPS and supraventricular tachycardia (SVT) ablation, and premature ventricular contraction ablation have all used isoproterenol as the primary provocative drug. [9] [10] [11] [12] [13] [14] [15] [16] Even under conditions of deep sedation or general anesthesia, isoproterenol is effective for arrhythmia induction. 17 However, as noted in prior publications, 18 isoproterenol. There is evidence that epinephrine induces sympathomimetic changes in the heart rate and blood pressure, 7, 20 but the effect on SVT arrhythmia induction during EPS remains unclear. Replacing isoproterenol with the less costly epinephrine seems a reasonable, but previously untested, option. The effect of this replacement on outcomes has not previously been reported. We evaluated the safety and efficacy of using epinephrine compared with isoproterenol for SVT arrhythmia induction during EPS.
| MATERIALS AND METHODS
We conducted a retrospective cohort study of all patients with evidence of clinical SVT who presented to St Vincent Hospital (Indianapolis, IN) for EPS and were tested with either isoproterenol or epinephrine, in an approximately 1-year period after the isoproterenol price change (6/1/2015-8/31/2016). SVT was defined as atrial tachycardia (AT), atrioventricular nodal re-entry tachycardia (AVNRT), or bypass tract mediated tachycardia (AVRT). We included those patients in whom drug infusion was required to assess baseline arrhythmia inducibility; patients in whom drug infusion was used only to test efficacy after ablation were excluded. 21 The choice and dosing of drug infusion was at the discretion of the provider. Typically, antiarrhythmic drugs (class I
[flecainide, propafenone, disopyramide, and mexilitine] or class III
[sotalol and dofetilide]) were discontinued five half-lives before EPS, and beta-blockers and nondihydropyridine calcium channel blockers discontinued 24 hours before EPS.
| Cohort design
We used a stepwise approach to cohort selection and database follow-up were ascertained from the electronic medical record. After database creation, a random number generator was used to choose 10% of the population for repeated manual chart review by a second abstractor, which resulted in no changes to the original database.
Institutional review board approval was obtained before the start of data collection. Billing codes were queried for procedures that included EPS and concurrent medication administration. Exclusions included those for whom medication administration was not required for induction of the arrhythmia, but instead was used to test inducibility after ablation (incorrect drug, 50), and those studies that did not involve SVT (atrial flutter or atrial fibrillation, 27). Total study population included 131 patients. CPT, current procedural terminology; EPS, electrophysiology study; SVT, supraventricular tachycardia sinus cycle length, assessment of AH and HV intervals, and anterograde atrioventricular conduction and retrograde ventriculoatrial conduction using both incremental pacing as well as extra stimulus pacing. SVT induction was attempted at baseline, and if no arrhythmias were inducible, either isoproterenol or epinephrine infusion was begun. Infusion was titrated at the discretion of the operator, targeting a 10% increase in baseline cycle length or the maximum tolerated dose, and EPS was performed again.
| Electrophysiology study

| Outcome parameters
The primary outcome was arrhythmia inducibility during EPS. Clear documentation of a sustained, clinical SVT by the primary operator was required to bin it as a positive study. Safety outcomes included procedural complications (vascular injury, cardiac tamponade requiring intervention, severe regurgitant valvular disease following ablation, hypotension, heart attack, stroke, or death). were compared using the Mann-Whitney U test, and the Pearson chi-square test was used for categorical variables. Variables that had a two-tailed P < 0.05 in bivariate analysis were considered in the multivariable regression model. Two-tailed P < 0.05 were considered statistically significant. Analyses were conducted using SPSS v 24 (IBM, Armonk, NY).
| Statistical methods
| RESULTS
The cohort included 131 patients, with a mean age of 40.1 ± 21.9
years and median follow-up of 0.97 years (0.2, 1.3) ( Table 1 ). There were more female than male patients, and beta-blockers were the most common preoperative medications. Isoproterenol was given in 72 patients, epinephrine in 56 patients, and three patients received both epinephrine and isoproterenol (all three were given epinephrine, failed arrhythmia induction, and were then given isoproterenol; counted as epinephrine group for baseline variables). The frequency of isoproterenol and epinephrine use is 
| Induced arrhythmias
Arrhythmias were inducible in 84 of 131 (64%) patients, but 22 of 75 (29%) of those given isoproterenol and 28 of 59 (47%) of those given epinephrine were found to be noninducible at EPS (three patients were given both isoproterenol and epinephrine). By Pearson chisquare analysis, this was statistically significant (P = 0.020), and the [34%]), as previously reported. 22, 23 There were no significant baseline clinical differences between those who received isoproterenol and those who received epinephrine during EPS. There were no significant differences in major complications between the two groups (one patient in the isoproterenol group had pericardial tamponade requiring pericardiocentesis; one patient in the epinephrine group had severe abdominal pain and hypotension during the case, and the procedure was terminated early). This was not significant (1/72 vs 1/59; P = 0.90). No patients died in the follow-up period.
Covariates that were significantly associated with successful arrhythmia induction on bivariate analysis included type of arrhythmia, with AVNRT being much more likely to be induced than the other arrhythmias (P = 0.000; Table 2 ). Additionally, a longer procedure time was associated with successful induction (OR, 1.009; 95% CI, 1.003-1.015; P = 0.002).
Induction agent, type of arrhythmia, and procedure duration were included in a multivariate logistic regression model. Only isoproterenol use remained significantly associated with successful arrhythmia induction (OR, 2.57; 95% CI, 1.002-6.59; P = 0.05).
| DISCUSSION
The dramatic increase in the price of isoproterenol after March 2015 has resulted in cost-effectiveness evaluations for its routine use during EPS. In our electrophysiology laboratory, for example, Abbreviations: AT, atrial tachycardia; AVNRT, atrioventricular nodal re-entry tachycardia; AVRT, bypass tract mediated tachycardia; EPS, electrophysiology study; SVT, supraventricular tachycardia.
there has been a rapid decline in isoproterenol use during EPS, replacing it with the nonspecific alpha and beta-adrenergic stimulant, epinephrine. This study demonstrates that isoproterenol is more effective than epinephrine in inducing SVT during EPS. However, epinephrine was effective for arrhythmia induction in the majority of patients (n = 31 of 59 [53%]) and there was no difference in safety outcomes.
Furthermore, it should be noted that in two of three patients who received both drugs, isoproterenol was also unable to induce an arrhythmia. And in 4 of 28 patients who had no inducible arrhythmias with epinephrine, 1.0 mg of atropine administration resulted in successful arrhythmia induction (all were AVNRT).
Because this was not the standard practice across all cases, the strategy of "epinephrine ± atropine" was not formally assessed in this study. Older studies have included a small series of patients requiring atropine for arrhythmia induction, but to our knowledge no formal comparison to isoproterenol has been published. 14, 24 Nevertheless, routine use of atropine in addition to epinephrine may diminish the apparent advantage of isoproterenol use. An exploratory analysis reclassifying those four failures as successes would render the induction rates insignificantly different (59% vs 71%; P = 0.12).
Also, complication rates were not significantly different between the isoproterenol and epinephrine groups. However, this cohort was relatively young (mean age, 40 years old) and healthy (only 8% had preexisting coronary artery disease); see Table 1 . In this study, neither drug was stopped because of new myocardial ischemia during infusion, but they should both be used with caution when myocardial ischemia may be present.
Interestingly, we found a correlation between the length of procedure and the likelihood of successful arrhythmia induction. This may have been because of more time spent in performing maneuvers or titrating medications, though there was an inverse correlation between the maximum dose of epinephrine and successful induction.
It appears that if epinephrine is going to work, it will work at lower doses (0.2 μg/kg/min) and titrating to higher doses may not give the incremental benefit. There was no such relationship between isoproterenol dose and induction success.
| Cost savings
The current cost savings associated with epinephrine use in place of isoproterenol are significant, approaching $1620 per procedure.
Before isoproterenol price changes, this difference was only $140 per procedure at our institution. This study highlights the broader implications of pharmaceutical price control and how this affects patient care. In the absence of clear data about effectiveness, trends in our EP laboratory reflect a switch from isoproterenol to epinephrine because of manufacturer related changes in isoproterenol price. It does appear that there has been a reduction in successful arrhythmia induction as a result of this switch. However, a strategy of adding atropine in refractory cases, or switching to isoproterenol only after epinephrine failure, may be reasonable options.
| LIMITATIONS
We created a retrospective cohort using billing codes. Incorrect billing could decrease the yield of the study population. We limited our study time to 1 year, to better assess the change in isoproterenol usage patterns, but a true effect was not seen until 8 
